eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | multiple myeloma |
| Symptom | C0341697|renal impairment |
| Sentences | 28 |
| PubMedID- 23996482 | renal impairment is frequent in patients with multiple myeloma and is correlated with an inferior prognosis. |
| PubMedID- 22022183 | However, some reports show that hsct may reverse renal impairment in patients with multiple myeloma and the prognosis of patients with hsct is not different from that of patients without renal involvement (4, 13). |
| PubMedID- 19930441 | Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of italian myeloma network gimema. |
| PubMedID- 22237937 | Cyclophosphamide-containing regimen (tcd) is superior to melphalan-containing regimen (mpt) in elderly multiple myeloma patients with renal impairment. |
| PubMedID- 22763386 | The role of thalidomide, bortezomib and lenalidomide in multiple myeloma patients presenting with renal impairment was evaluated in 133 consecutive newly diagnosed patients who were treated with a novel agent-based regimen. |
| PubMedID- 23592895 | Objective: to investigate the efficacy and safety of the treatment of the newly diagnosed multiple myeloma (mm) with or without renal impairment receiving the therapy of bortezomib, dexamethasone plus thalidomide (btd) regimen in order to analyze the effects of btd regimen on the prognosis of the mm patients with renal impairment compared with the patients without renal impairment. |
| PubMedID- 24064839 | renal impairment in multiple myeloma and related disorders. |
| PubMedID- 20479544 | Aims: this retrospective study investigated the rates of renal impairment in patients with multiple myeloma treated with zoledronic acid and ibandronate. |
| PubMedID- 20956629 | renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. |
| PubMedID- 22541094 | Relationship between the catalysis of bence jones protein and renal impairment in patients with multiple myeloma. |
| PubMedID- 22739170 | This study was purposed to analyze the clinical characteristics of multiple myeloma (mm) patients with and without renal impairment (ri) and to investigate the effect of bortezomib (bor) on mm with ri. |
| PubMedID- 22282247 | renal impairment in multiple myeloma: presenting features in different departments. |
| PubMedID- 25829094 | Likewise, in two prospective clinical studies and one retrospective study of myeloma patients with moderate-to-severe renal impairment or renal failure/dialysis, bendamustine in combination with other drugs (prednisone and bortezomib, or thalidomide and dexamethasone) was well tolerated.fig. |
| PubMedID- 23364621 | Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. |
| PubMedID- 25083819 | Reversal of renal dysfunction significantly affects the prognosis of multiple myeloma (mm) with renal impairment (ri). |
| PubMedID- 26117025 | Clinical research about risk factors and reversible predictors in renal impairment due to multiple myeloma. |
| PubMedID- 21343553 | renal impairment in multiple myeloma: time is of the essence. |
| PubMedID- 24425688 | Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment. |
| PubMedID- 21778706 | This report presents the totality of evidence through a systematic review that assessed either the efficacy or safety of bortezomib-based regimens in multiple myeloma with renal impairment. |
| PubMedID- 25246256 | Clinical characteristics of multiple myeloma with renal impairment and the efficacy of different treatments. |
| PubMedID- 22739205 | Catalytic activity of bence jones proteins in renal impairment of patients with multiple myeloma - review. |
| PubMedID- 25003848 | Conclusion: high dose treatment and novel drugs, especially bortezomib, can effectively overcome the negative impact of renal impairment in patients with multiple myeloma. |
| PubMedID- 21654882 | Given the incidence of renal impairment in patients with myeloma, an organ dysfunction study (px-171-005) was performed by bardos et al.51,52 thirty-nine patients were enrolled into the study. |
| PubMedID- 23384902 | Exploration of early assessment of renal impairment in multiple myeloma. |
| PubMedID- 21973045 | Background: reversal of renal impairment (ri) in patients with multiple myeloma (mm) has been evaluated using the estimated glomerular filtration rate (egfr(mdrd) ) formula developed by the modification of diet in renal disease study group. |
| PubMedID- 23829647 | Results: ckd-epi-scr-cysc equation detected more myeloma patients with stage 3-5 renal impairment than the mdrd, ckd-epi, or ckd-epi-cysc equations: 45% vs. |
| PubMedID- 21951682 | Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (vmpt-vt) versus bortezomib-melphalan-prednisone (vmp) in untreated multiple myeloma patients with renal impairment. |
| PubMedID- 21403430 | The present study demonstrated that bd therapy was highly effective for the treatment of japanese myeloma patients with renal impairment. |
Page: 1